Praxis Precision Medicines, Inc. PRAX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s additional paid-in capital?
- Praxis Precision Medicines, Inc. (PRAX) reported additional paid-in capital of $2.64B in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s additional paid-in capital changed year-over-year?
- Praxis Precision Medicines, Inc.'s additional paid-in capital increased by 96.6% year-over-year, from $1.34B to $2.64B.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s additional paid-in capital has grown at a 35.8% compound annual growth rate (CAGR), from $437.01M to $2.02B.
- What does additional paid-in capital mean?
- Capital contributed by investors above the par value of the shares.
- How do you interpret additional paid-in capital?
- Higher values indicate successful equity fundraising rounds, which are critical for funding R&D pipelines.
- How does additional paid-in capital compare across companies?
- High levels are typical for growth-stage biotech firms that rely on equity financing to fund clinical trials.